Kornela Kotseva

Professor Kornelia Kotseva holds an appointment as Honorary Professor of Preventive Cardiology and Head of Research at the National Institute for Prevention and Cardiovascular Health, College of Medicine, Nursing and Health Sciences, School of Medicine, National University of Galway, Ireland, and a position as Consultant Cardiologist at the Imperial College Healthcare NHS Trust, London, UK. Prior to this she had academic appointments at the National Heart & Lung Institute, Imperial College London, UK and at the Department of Public Health, Ghent University, Belgium.

She has been a Chair of the Steering Committee of the ESC EUROASPIRE IV and V surveys, aiming to describe the risk factor management in patients with coronary disease and in people at high cardiovascular risk in Europe.  Furthermore, she was a Principal Investigator or Co-Investigator of several other European and UK studies: EUROASPIRE III Health Economics, ASPIRE-2-PREVENT, ASPIRE-3-PREVENT, ASPIRE-TO-ACTION, EUROACTION and EUROACTION PLUS randomised controlled trials, the productivity losses and indirect costs after cardiovascular events in Europe, the Heart Quality of Life (HeartQoL) and other studies. She acted as an expert panel member of the World Heart Federation Roadmap programme of the cardiovascular disease prevention among people with diabetes, the Euro Heart Index and the EU funded EConDA project on cost-effectiveness for chronic diseases. She is a member of the Executive Committee of the World Heart Federation/ European Society of Cardiology INTERASPIRE survey in six WHO regions and the forthcoming European Society of Cardiology EUROASPIRE VI survey.

Professor Kotseva has won numerous prestigious awards and has authored more than 250 publications in peer reviewed journals, two textbooks and chapters for a further eight textbooks. She is serving as Editorial Board member of the American Journal of Preventive Cardiology and American Journal of Cardiovascular Drugs.

Her main research and clinical interest is the primary and secondary prevention of cardiovascular disease.